REVIEW OF SAFETY AND TOLERANCE OF OMALIZUMAB
The review of safety of monoclonal anti-ige-antibodies (xolair) - a new medication for the treatment of severe allergic bronchial asthma is presented. Local and system adverse events, originating after injection of medicament in clinical studies and following administration in patients are discussed...
Saved in:
Main Author: | A.V. Emel'yanov (Author) |
---|---|
Format: | Book |
Published: |
"Paediatrician" Publishers LLC,
2008-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
REVIEW OF SAFETY AND TOLERANCE OF OMALIZUMAB
by: A.V. Emel'yanov
Published: (2008) -
Urticaria and angioedema as possible reactions of omalizumab
by: Ozlem Ozbagcivan, et al.
Published: (2018) -
Omalizumab-A review
by: Kiran Godse, et al.
Published: (2015) -
Complete response to dupilumab in a patient with chronic spontaneous urticaria who did not tolerate omalizumab
by: Changhua Zhu, MD, et al.
Published: (2023) -
OMALIZUMAB IN TREATMENT FOR ALLERGIES
by: T.V. Kulichenko
Published: (2007)